TD Cowen Downgrades Moderna to Market Perform, Lowers Price Target to $125
Portfolio Pulse from richadhand@benzinga.com
TD Cowen analyst Tyler Van Buren has downgraded Moderna (NASDAQ:MRNA) from Outperform to Market Perform and lowered the price target from $145 to $125.
August 04, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Moderna's stock rating has been downgraded by TD Cowen, with a lowered price target, which could negatively impact the stock's performance.
The downgrade from Outperform to Market Perform by TD Cowen indicates a less optimistic outlook for Moderna's stock. The lowered price target from $145 to $125 also suggests that the analyst believes the stock may not perform as well as previously expected. This could lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100